Portola Pharmaceuticals Revenue and Competitors

Location

$1.3B

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Portola Pharmaceuticals's estimated annual revenue is currently $24M per year.(i)
  • Portola Pharmaceuticals received $345.0M in venture funding in September 2017.
  • Portola Pharmaceuticals's estimated revenue per employee is $363,636
  • Portola Pharmaceuticals's total funding is $1.3B.

Employee Data

  • Portola Pharmaceuticals has 66 Employees.(i)
  • Portola Pharmaceuticals grew their employee count by -4% last year.

Portola Pharmaceuticals's People

NameTitleEmail/Phone
1
Scientist IReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Portola Pharmaceuticals?

We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. The company's two FDA approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$1.3B

Total Funding

66

Number of Employees

$24M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Portola Pharmaceuticals News

2022-04-20 - Allergic Conjunctivitis Treatments Market Size, Outlook And ...

Aldeyra Therapeutics, Allergan, OHR Pharmaceutical, Portola Pharmaceuticals, Sylentis, Bausch + Lomb. This comprehensive Allergic Conjunctivitis Treatments...

2022-04-20 - Non-Receptor Tyrosine Protein Kinase TYK2 Market Size ...

Array BioPharma Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Bristol-Myers Squibb ... Takeda Pharmaceutical Company Ltd, and Theravance Biopharma Inc.

2022-04-17 - Anticoagulant Reversal Drugs Market is Expected to Exhibit a ...

Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc | Medgadget...

2019-09-08 - Portola Pharmaceuticals Announces Pricing of Public Offering ...

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.3M66-3%$80.9M
#2
$5.1M6610%$316M
#3
$9.3M693%N/A
#4
$17.6M706%N/A
#5
$15M720%N/A

Portola Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2003-12-09$21.0MAMultipleArticle
2005-01-19$21.0MASutter Hill Ventures, Prospect VenturesArticle
2005-11-09$46.0MBAdvanced Technology VenturesArticle
2006-10-18$20.0MUndisclosedHercules Technology Growth CapArticle
2007-05-08$70.0MCMultipleArticle
2008-07-10$60.0MUndisclosedMultipleArticle
2011-11-22$89.0MUndsiclosedTemasekArticle
2014-10-06$185.4MUndisclosedMorgan StanleyArticle
2015-03-11$100.0MUndisclosedMorgan StanleyArticle
2017-09-13$345.0MUndisclosedMorgan StanleyArticle